Bio-Rad ddPCR COVID-19 Assay Secures FDA Emergency Use Authorization
By LabMedica International staff writers Posted on 05 May 2020 |
Image: QX200 AutoDG Droplet Digital PCR (Photo courtesy of Bio-Rad Laboratories, Inc.)
Bio-Rad Laboratories, Inc.’s (Hercules, CA, USA) SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit which runs on its QX200 and QXDx ddPCR systems has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA).
The SARS-CoV-2 ddPCR test represents the latest addition to Bio-Rad’s product offerings related to COVID-19 and is the second EUA that has been granted to the company for COVID-19. Last week, Bio-Rad had secured EUA for its serology test to detect antibodies to the virus.
The high sensitivity of Bio-Rad’s single-well SARS-CoV-2 ddPCR test makes it well suited to screening upper respiratory samples in patients with a low viral load, including individuals in the early stages of infection as compared to classical quantitative PCR tests. The test can also play an important role in surveillance by detecting minimal residual disease in people recovering from COVID-19 and informing them if they are negative for the virus. It also provides clinicians with a high degree of sensitivity that can significantly improve the accuracy of reported results. Thousands of hospitals and molecular testing labs in the US and around the world have installed Bio-Rad’s QX200 and QXDx ddPCR systems and have the capacity to perform SARS-CoV-2 ddPCR testing.
“We are pleased to receive Emergency Use Authorization for our SARS-CoV-2 ddPCR test that offers high sensitivity in detecting infection of COVID-19 at an early stage,” said Simon May, Senior Vice President of Bio-Rad’s Digital Biology Group. “We believe the test will be a powerful complement to current diagnostics, helping clinicians and public health officials accurately identify infected individuals in a timely manner. With the EUA, our test is now available to clinical labs in the US.”
The SARS-CoV-2 ddPCR test represents the latest addition to Bio-Rad’s product offerings related to COVID-19 and is the second EUA that has been granted to the company for COVID-19. Last week, Bio-Rad had secured EUA for its serology test to detect antibodies to the virus.
The high sensitivity of Bio-Rad’s single-well SARS-CoV-2 ddPCR test makes it well suited to screening upper respiratory samples in patients with a low viral load, including individuals in the early stages of infection as compared to classical quantitative PCR tests. The test can also play an important role in surveillance by detecting minimal residual disease in people recovering from COVID-19 and informing them if they are negative for the virus. It also provides clinicians with a high degree of sensitivity that can significantly improve the accuracy of reported results. Thousands of hospitals and molecular testing labs in the US and around the world have installed Bio-Rad’s QX200 and QXDx ddPCR systems and have the capacity to perform SARS-CoV-2 ddPCR testing.
“We are pleased to receive Emergency Use Authorization for our SARS-CoV-2 ddPCR test that offers high sensitivity in detecting infection of COVID-19 at an early stage,” said Simon May, Senior Vice President of Bio-Rad’s Digital Biology Group. “We believe the test will be a powerful complement to current diagnostics, helping clinicians and public health officials accurately identify infected individuals in a timely manner. With the EUA, our test is now available to clinical labs in the US.”
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants